PA32540: Additional Phase I data

Additional data from the open-label, crossover Phase I Co-Rx trial in 30 healthy volunteers showed that PA32540 plus Plavix clopidogrel led to significantly greater inhibition of adenosine diphosphate (ADP)-induced platelet aggregation vs. standard of care (46.5% vs. 39.9%, respectively; p=0.004). Subjects received PA32540 in the morning plus 300 mg Plavix over 10 hours later on day 1, followed by PA32540 in the morning plus 75 mg Plavix 10 hours later on days 2-7; or standard of care consisting of 81 mg enteric-coated aspirin, 300 mg Plavix and 40 mg enteric-coated omeprazole all dosed in the morning on day 1, followed by 81 mg enteric-coated aspirin, 75 mg Plavix and 40 mg enteric-coated omeprazole all dosed in the morning on days 2-7. Data were presented at the European Society of Cardiology meeting in Munich. ...